<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01550653</url>
  </required_header>
  <id_info>
    <org_study_id>Ott-NN-001</org_study_id>
    <nct_id>NCT01550653</nct_id>
  </id_info>
  <brief_title>Liraglutide Effects on Memory in Healthy Subjects</brief_title>
  <official_title>Liraglutide Effects on Memory in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Luebeck</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the hypothesis, that subcutaneous administration of liraglutide, an
      analogue of the incretin glucagon-like peptide 1, over 5 weeks improves memory functions in
      healthy humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the immediate and delayed recall of a declarative memory task (word list recall) at time points indicated in &quot;time frame&quot; section.</measure>
    <time_frame>Day -7 (immediate Recall 1), Day 0 (Delayed Recall 1), Day 1 (Immediate Recall 2), Day 7 (Delayed Recall 2), Day 28 (Immediate Recall 3), Day 35 (Delayed Recall 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in the immediate and delayed recall of an Episodic Memory Task (story recall) at the time points indicated in the &quot;Time Frame&quot; - section.</measure>
    <time_frame>Day -7 (immediate Recall 1), Day 0 (Delayed Recall 1), Day 28 (Immediate Recall 2), Day 35 (Delayed Recall 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in performance on a two-dimensional object location task on day 1 and day 35.</measure>
    <time_frame>Day -7, Day 1, Day 35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in performance on a working-memory task on day 1 and day 35.</measure>
    <time_frame>Day -7, Day 1, Day 35</time_frame>
    <description>Digit Span Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in immediate and delayed recall of a procedural memory task at the time points indicated in the &quot;Time Frame&quot; - section.</measure>
    <time_frame>Day -7 (immediate Recall 1), Day 0 (Delayed Recall 1), Day 28 (Immediate Recall 2), Day 35 (Delayed Recall 2)</time_frame>
    <description>Finger tapping test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in resting metabolic rate on day 7, 28 and 35.</measure>
    <time_frame>Day 0 , Day 7 , Day 28 , Day 35</time_frame>
    <description>indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum/plasma concentrations of parameters involved in glucose metabolism on day 1,7,28, and 35.</measure>
    <time_frame>Day -7, 1, 7, 28, 35</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See &quot;Intervention&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>See &quot;Intervention&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Subcutaneous self-administration of liraglutide(Victoza)by pen. The starting dose is 0.6 mg once daily(day 0 to 7), followed by 1.2 mg once daily (day 8 to 35).</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male sex

          -  Age 18-35 years

          -  Body mass index between 19 and 25 kg/m2

          -  Non-smoker

        Exclusion Criteria:

          -  Receipt of any drug within 4 weeks prior to this trial

          -  Any known acute or chronic disease of the brain, heart, lung, kidney,liver, pancreas
             or gastrointestinal tract, any metabolic, endocrine or psychiatric disease.

          -  Brady- and Tachycardia, i.e. heart rate &lt; 50 and &gt; 90 beats per minute.

          -  Hypertension (systolic blood pressure &gt; 150 mmHg, diastolic blood pressure &gt; 90 mmHg).

          -  Hyperlipidemia (cholesterol, LDL, triglyceride &gt; two times the upper reference limit
             based on analysis from the central laboratory)

          -  Impaired hepatic function measured as alanine aminotransferase (ALAT) &gt; two times the
             upper reference limit based on analysis from the central laboratory

          -  Impaired renal function measured as creatinine &gt; 120 Âµmol/l based on analysis from the
             central laboratory

          -  Family history of diabetes

          -  History of any eating disorder

          -  Known or suspected allergy to trial products

          -  History of drug or alcohol abuse within the last five years prior to screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Ott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Luebeck, Department of Neuroendocrinology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Luebeck, Department of Neuroendocrinology</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <last_update_submitted>February 26, 2014</last_update_submitted>
  <last_update_submitted_qc>February 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Luebeck</investigator_affiliation>
    <investigator_full_name>Dr. med. Volker Ott</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Memory</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>energy output</keyword>
  <keyword>Memory facilitation</keyword>
  <keyword>GLP-1 analogue</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

